NeuroScientific Biopharmaceuticals Ltd (ASX: NSB, “NeuroScientific”) has announced it has received the Final Report from its recently completed glaucoma animal study.
What are the key highlights?
- Neuroscientific’s lead drug candidate, called EmtinB, demonstrated neuroprotection across multiple highly relevant study end points.
- EmtinB did not cause any toxicity in the tissues analysed during the study, as evidenced by negative results for both TUNEL and Caspase 3 toxicity biomarkers.
- NeuroScientific is progressing the safety and toxicology program of EmtinB to be concluded in the second half of this year with first human studies scheduled for later this year.
Please refer to the announcement linked below for further details.